Top Ten most popular articles on Pharmafile.com this week
pharmafile | March 27, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | COVID-19, coronavirus
The COVID-19 global pandemic continues to dominate the news cycle. The first clinical trial using danoprevir (Ganovo) in treating COVID-19 has released its results, showing that it is safe and well tolerated in patients, while Dr Anthony Fauci, the Director of the National Institute of Allergy and Infectious Disease in the US, said that people between the ages of 20 and 44 have been more seriously impacted by the coronavirus in Europe and the US compared to China.
In non-coronavirus news, ViiV Healthcare has secured its first global approval for its once-monthly treatment Cabenuva, it has emerged, to replace current antiretroviral regimens for the treatment of HIV-1 infection in adult patients in Canada, while the FDA has chosen not to approve an expanded indication of 2.5mg Jardiance (empaglifozin) as an adjunct to insulin in the treatment of type 1 diabetes.
10. More young coronavirus patients being hospitalised in Europe and US compared to China
Dr Anthony Fauci, the Director of the National Institute of Allergy and Infectious Disease in the US, said that people between the ages of 20 and 44 have been more seriously impacted by the coronavirus in Europe and the US compared to China.
9. ViiV Healthcare scores world-first approval in Canada for monthly HIV regimen Cabenuva
ViiV Healthcare has secured its first global approval for its once-monthly treatment Cabenuva, it has emerged, to replace current antiretroviral regimens for the treatment of HIV-1 infection in adult patients in Canada.
8. NICE and EMA to review if Ibuprofen and other anti-inflammatories worsen coronavirus
The National Institute for Health and Care Excellence (NICE) and the European Medicines Regulatory have both stated that there is currently no evidence anti-inflammatory over the counter drugs worsen symptoms of COVID-19, but will investigate the matter.
7. British government protecting high demand medicine for use in COVID-19 patients
The British government has implemented new restrictions to protect high demand medicines for coronavirus patients.
6. FDA will allow doctors to use convalescent plasma to treat critical COVID-19 patients
The FDA have announced they will allow doctors to use convalescent plasma, collected from people who recovered from COVID-19, to treat those who are in critical condition from the virus.
Novartis has revealed five-year data on its gene therapy Zolgensma, boasting that the one-time infusion demonstrated “rapid, significant and clinically meaningful therapeutic benefit” in spinal muscular atrophy (SMA) patients.
Gilead Sciences has submitted a request for the FDA to rescind its offer of Orphan Drug designation for remdesivir in treating coronavirus, after a huge public backlash.
3. Drug launches across Europe will be affected by coronavirus
The COVID-19 pandemic will affect European launches of drugs for a host of diseases including HIV, cancer and sickle cell disease, according to analysts.
2. FDA turns down label expansion for Jardiance as an adjunct to insulin in type 1 diabetes
The FDA has chosen not to approve an expanded indication of 2.5mg Jardiance (empaglifozin) as an adjunct to insulin in the treatment of type 1 diabetes.
1. Results released from first clinical trial using Danoprevir to treat COVID-19
The first clinical trial using danoprevir (Ganovo) in treating COVID-19 has released its results, showing that it is safe and well tolerated in patients.
Related Content
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …
